New Clinical Trials Launch as Cancer Treatment Studies Advance

A new remote clinical trial, entitled SUCCEED, has launched to help patients with small cell lung cancer participate in the study from home, addressing location barriers to care that have limited research in this aggressive disease.

Meanwhile, updated data from ovarian cancer and advanced solid tumor trials were announced, and a phase 1b study for urothelial cancer began dosing patients, reflecting ongoing efforts to develop new treatments across several hard-to-treat cancers.

Remote Trial for Small Cell Lung Cancer

SUCCEED, a landmark observational clinical study that allows patients with small cell lung cancer to participate remotely, has launched to address one of the least researched cancer types, according to a news release from GO2 for Lung Cancer. The study is led by GO2 for Lung Cancer and the Addario Lung Cancer Medical Institute.

The SUCCEED study will evaluate whether a remote, direct-to-patient approach is effective for people with small cell lung cancer while collecting their blood samples. These samples will be stored in a biobank and may be used in future research to help develop new treatments.

The study uses a remote, decentralized model that enables people with small cell lung cancer anywhere in the U.S. to join and take part from home. This design helps include patients who might otherwise be excluded, such as those who are older, live far from treatment centers, or have other serious health conditions. Because small cell lung cancer advances quickly, these barriers have often kept patients from joining clinical trials in the past, as per the release.

New Trial to Be Launched for Ovarian Cancer

A phase 1b study of NXP800 for recurrent ovarian cancer with platinum resistance and ARID1a mutations has released its final clinical data update; the update reported on the progress towards launching the phase 1b trial for NXP900, according to a news release from NuvectisPharma.

NXP800 is an oral small molecule that activates GCN2, a protein that helps cancer cells respond to stress, and has shown anti-cancer activity in recurrent, platinum-resistant ovarian cancer with ARID1a mutations.

Overall, treatment with NXP800 led to two patients having an unconfirmed partial response and three patients having stable disease. In the phase 1b study, 17 patients with recurrent, platinum-resistant ovarian cancer with ARID1a mutations received 75 milligrams of NXP800 daily or intermittently, with data available for 13 patients.

Thrombocytopenia, a side effect that lowers platelet levels, was an early concern in the study but was successfully managed by switching to intermittent dosing. The company will not continue developing NXP800 for ovarian cancer but plans to explore its use in other cancers, like endometrial and prostate cancer, where patients’ overall health may allow for better treatment outcomes, as per the release.

Treatment in Advanced Solid Tumor Trial Completed

The multicenter, phase 1b/2a INJECTABL-1 trial of IP-001 for advanced colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma has completed treatment of its last patient after enrolling 41 patients across France, Germany, Switzerland, the UK, and the US, according to a news release from Immunophotonics.

The trial was designed to assess the systemic immune-mediated anti-cancer effects of IP-001 after tumor ablation, which destroys all cells in targeted tumors but does not trigger a strong immune response in patients with advanced solid tumors.

IP-001 is a proprietary glycan polymer that forms tumor antigen depots and serves as a powerful immune stimulant. It is designed to extend the presence of tumor antigens, attract and activate innate immune cells such as antigen-presenting cells, enhance the uptake of tumor antigens by these cells, and stimulate a systemic adaptive immune response that enables immune cells to find and destroy cancer cells throughout the body.

Tumor ablation is a well-established, approved procedure widely available at hospitals and clinics, and IP-001 is a novel immunotherapy injected directly into the ablation zone to retain tumor debris and antigens while activating the patient’s immune system for systemic tumor surveillance, allowing the body to recognize and eliminate tumor cells that escaped the treated metastatic lesion.

First Patient Dosed With FX-909 in Urothelial Cancer Trial

The first patient has been dosed in a phase 1b clinical trial evaluating FX-909, an oral small molecule that inhibits PPARG, a key regulator of the luminal lineage, for treating locally advanced or metastatic urothelial cancer, according to a news release from Flare Therapeutics.

FX-909 demonstrated clinical proof-of-concept as a monotherapy in a phase 1a study based on pre-set criteria. The company expects to share these results at a scientific conference in 2025.

The phase 1b trial will assess safety and effectiveness to establish the recommended Phase 2 dose in patients selected by a biomarker. A validated immunohistochemistry test is being used to identify patients with the key transcription factor involved in tumor development. The study will test 30 milligrams and 50 milligrams once-daily doses in a two-stage design, enrolling around 40 patients.

The company plans to report efficacy data for a biomarker-defined population at the recommended phase 2 dose in early 2026. More information about the trial is available at clinicaltrials.gov under identifier NCT05929235.

References

1. "GO2 for Lung Cancer and ALCMI Launch SUCCEED, a Groundbreaking Remote Clinical Study Targeting Small Cell Lung Cancer," GO2 for Lung Cancer. News Release. July 2025.
2. "Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study," Nuvectis Pharma. News Release. July 31, 2025.
3. "Immunophotonics Completes Treatment of Last Patient in INJECTABL-1 Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors," Immunophotonics. News Release. 2025.
4. "Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer," Flare Therapeutics. News Release. August 5, 2025.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.